what does data from the phase iii commands trial reveal about luspatercept as a treatment option?
Published 10 months ago • 40 plays • Length 4:12Download video MP4
Download video MP3
Similar videos
-
1:06
commands trial: luspatercept vs epoetin alfa in lower-risk mds
-
7:14
phase iii medalist trial of luspatercept for mds
-
5:30
commands: luspatercept vs epoetin alfa for anemia in esa-naive lr-mds
-
4:00
real-world data on the efficacy of luspatercept in lr-mds
-
6:32
luspatercept reduces transfusion burden in mds-related anemia: medalist results
-
14:41
luspatercept compared with other available therapies for mf
-
7:18
how might luspatercept benefit patients with myelofibrosis?
-
6:31
results from the medalist trial for patients with anaemia in mds
-
2:26
ace-536-mf-001 update: luspatercept for the treatment of anemia in myelofibrosis
-
4:35
lower-risk mds in 2021: luspatercept, imetelstat & roxadustat
-
3:01
long-term results of believe: luspatercept in adults with transfusion-dependent beta-thalassemia
-
1:40
long-term follow-up of luspatercept: response duration and progression to aml
-
24:49
how i treat” a patient with lower-risk mds showing signs of esa failure
-
1:37
phase iii independence trial of luspatercept in patients with td myelofibrosis on jaki therapy
-
2:15
independence: luspatercept vs placebo in mpns-associated myelofibrosis
-
2:02
beyond trial update: luspatercept in non-transfusion-dependent β-thalassemia
-
0:48
an introduction to the maxilus study: the optimal dose of luspatercept in lr-mds
-
7:39
program update | expanded beta phase